RedChip Visibility Initiates Research Coverage on CellCyte Genetics Corp.

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

Bothell (euro adhoc) - ORLANDO, Fla., June 3 -- RedChip Visibility, a division
of RedChip Companies, Inc., has initiated coverage on CellCyte Genetics Corp.
(OTC Bulletin Board: CCYG), a biotechnology firm engaged in the discovery and
development of stem cell therapeutic products and medical devices for cell
production.
Ajay Mohan, MFM, RedChip Research Analyst, reported: "CCYG is developing a
breakthrough technology that may improve stem cell delivery and retention
mechanisms to selected organs using a patient's circulatory system. Delivery of
stem cells to the specific organ is currently one of the most challenging tasks
in stem cell studies. The application of this technology is unlimited and could
be used in a large number of cases such as heart, liver, or kidney failure and
neurological disorders."
"The Company is in the process of taking this technology to the human trials
phase, and the first organ for this trial is the heart. The difficulty so far
has been that stems cells do not stay in the heart or other organ; rather, they
flow down and accumulate in the liver or spleen. CCYG has discovered a mechanism
by which certain receptors are blocked in the liver and spleen with the compound
CCG-TH30 or CCG-TH35 and is believed to allow stem cells to remain in the heart
or potentially other organs," Mohan continued.
"The biotech industry in general is moving towards a mature stage, but stem
cell research is a strong emerging segment within the industry. We are
initiating coverage of CCYG with a 'Speculative Buy' recommendation and a
12-month target price of US$0.80," he concluded.
To receive a complimentary copy of the RedChip Visibility Initial Research
Report for CellCyte Genetics Corp., please visit:
http://www.redchip.com/visibility/about.asp?page=vreport&reportid=112&from=05292008pr

About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial
public relations firm with offices in Maitland, Florida; Bangalore, India; and
Beijing, with affiliates in New York and San Diego. RedChip delivers concrete,
measurable results for its clients through its extensive national and
international network of small-cap institutional and retail investors. RedChip
has developed the most comprehensive platform of products and services for
small-cap companies, including: RedChip Research(TM), Traditional Investor
Relations, Digital Investor Relations, Institutional and Retail Conferences,
RedChip Internet TV(TM), and RedChip Radio(TM). To learn more about RedChip's
products and services please visit:
http://www.redchip.com/visibility/productsandservices.asp.

The RedChip Companies, Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=2761

DISCLOSURE: None of the profiles issued by RedChip Companies, Inc.,
constitutes a recommendation for any investor to purchase or sell any particular
security or that any security is suitable for any investor. CellCyte Genetics
Corp. paid RedChip Visibility, a division of RedChip Companies, Inc., US$36,000
for RedChip Visibility Program services, which included the preparation of this
equity research report. To the fullest extent permitted by law, RedChip
Companies, Inc., will not be liable to you or anyone else under any tort,
contract, negligence, strict negligence, strict liability, products liability,
or other theory with respect to this presentation of information.

For Further Information, Contact:
RedChip Companies, Inc.
500 Winderley Place, Suite 100, Maitland, FL 32751, +1-800-733-2447
Fax: +1-407-644-0758, [email protected]

SOURCE RedChip Companies, Inc.
-0- 06/03/2008
/Web site: http://www.cellcyte.com /

Further inquiry note:
RedChip Companies, Inc., +1-800-733-2447, Fax, +1-407-644-0758, [email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: CellCyte Genetics Corporation
220th Street SE, Suite 103 1725
US-98021 Bothell
phone: +1 425 483 6101
FAX: +1 425 483 6591
mail: [email protected]
WWW: http://www.cellcyte.com
sector: Biotechnology
ISIN: US15116P1030
indexes:
stockmarkets: Open Market: Börse Frankfurt, free trade: Börse Berlin, Börse
Stuttgart, Börse München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print